Clinical Immunology Laboratory, North Hospital, CHU of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France.
Exp Mol Pathol. 2013 Feb;94(1):115-20. doi: 10.1016/j.yexmp.2012.10.005. Epub 2012 Oct 9.
Our objective was to evaluate the levels of miR-210 in tumor and serum samples of conventional renal cell cancer (cRCC) patients to explore whether circulating miR-210 in serum can be used as a biomarker for the detection of cRCC.
The paired samples from primary cRCC tumors and adjacent non-tumoral renal parenchyma were collected from 32 patients with cRCC. Serum samples were obtained from 68 patients with a cRCC before surgery, 10 samples after one week of surgery, and 42 healthy individuals were included in this study. Real-time PCR was used to measure the microRNA level. The expression of miRNAs was normalized using the dCT method. Expression levels of miR-210 were compared using the Mann-Whitney U test or Wilcoxon test. Diagnostic performance of serum miR-210 level was calculated by using the receiver operating characteristic (ROC) curve.
The average miR-210 level was higher in primary cRCC tissues than in normal tissue (p=0.004). For serum samples, the average level of miR-210 was significantly higher in cRCC patients than in controls (p<0.001). The serum miR-210 level yielded an AUC (the areas under the ROC curve) of 0.874 with a sensitivity of 81.0% and a specificity of 79.4%. Furthermore, the average serum level of miR-210 was significantly decreased in the patients one week after the operation (p=0.001).
Serum mi-210 may have a potential as a novel noninvasive biomarker for the detection of cRCC.
本研究旨在评估常规肾细胞癌（cRCC）患者肿瘤和血清样本中 miR-210 的水平，以探讨血清中循环 miR-210 是否可作为检测 cRCC 的生物标志物。
收集 32 例 cRCC 患者的原发性 cRCC 肿瘤和相邻非肿瘤性肾实质的配对样本。本研究纳入了 68 例 cRCC 患者手术前的血清样本、手术后 1 周的 10 个样本和 42 名健康个体。采用实时 PCR 测定 miRNA 水平。采用 dCT 法对 miRNA 的表达进行归一化。采用 Mann-Whitney U 检验或 Wilcoxon 检验比较 miR-210 的表达。采用受试者工作特征（ROC）曲线计算血清 miR-210 水平的诊断性能。
原发性 cRCC 组织中的平均 miR-210 水平高于正常组织（p=0.004）。对于血清样本，cRCC 患者的平均 miR-210 水平显著高于对照组（p<0.001）。血清 miR-210 水平的 AUC（ROC 曲线下的面积）为 0.874，灵敏度为 81.0%，特异性为 79.4%。此外，术后 1 周患者的血清 miR-210 平均水平显著降低（p=0.001）。
血清 miR-210 可能作为一种新型的无创生物标志物，用于检测 cRCC。
